Stomach cancer primary prevention
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2] Mohammed Abdelwahed M.D[3]
Stomach cancer Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Stomach cancer primary prevention On the Web |
American Roentgen Ray Society Images of Stomach cancer primary prevention |
Risk calculators and risk factors for Stomach cancer primary prevention |
Overview
Effective measures for the primary prevention of stomach cancer include smoking cessation, eradication of Helicobacter pylori infection, and having a balanced diet rich in fruits and vegetables. In areas of low gastric cancer incidence, screening for gastric cancer with upper endoscopy should be reserved for specific high-risk subgroups. Individuals at increased risk for gastric cancer include; gastric adenomas, pernicious anemia, gastric intestinal metaplasia, familial adenomatous polyposis, Lynch syndrome, Peutz-Jeghers syndrome, Juvenile polyposis syndrome.
Primary prevention
Lifestyle modifications
Lifestyle modifications include following:[1]
- Dietary modification is an important approach to control gastric cancer. There is a link between physical inactivity and obesity to many types of cancer.
- Diet with low consumption of red meat, high in fruits and vegetables may have a protective effect against many cancers.
- The World Health Assembly adopted the WHO Global Strategy on Diet, Physical Activity, and Health, in May 2004 to reduce deaths and diseases.
H.pylori eradication
- The incidence of metachronous gastric cancer following the endoscopic resection of a gastric neoplasm is known to be reduced by the eradication of H. pylori infection. [1][2]
Prevention Through Screening
- In countries with a high incidence of gastric cancer such as east Asia countries, universal screening is recommended. ?
- Japan has a high incidence of gastric cancer; therefore annual screening via double contrast barium radiography and photofluorography every year or upper endoscopy every two to three years.?
- Screening interval is recommended to be every two years but may be extended to a three-year interval without significant difference in effect. ??
Prevention of Hereditary Cancer
Screening
- In areas of low gastric cancer incidence, screening for gastric cancer with upper endoscopy should be reserved for specific high-risk subgroups
- Individuals at increased risk for gastric cancer include those with the following:
- Gastric adenomas
- Pernicious anemia
- Gastric intestinal metaplasia
- Familial adenomatous polyposis
- Lynch syndrome
- Peutz-Jeghers syndrome
- Juvenile polyposis syndrome
Prevention
- Asymptomatic patients with a family history of HDGC and CDH1 mutations have a high probability of developing signet ring cell adenocarcinoma of the stomach. Prophylactic total gastrectomy is recommended for patients with family history of HDGC and CDH1 mutations.[3]
- For patients with a CDH1 mutation but who are not from an HDGC family, individualized evaluation at an experienced center before prophylactic total gastrectomy is recomended.[4]
- Prophylactic gastrectomy is often advised between age 20 and 30.
- Some suggest timing total gastrectomy in CDH1 mutation carriers at an age that is five years younger than the youngest family member who developed gastric cancer.[5]
- Older patients are less likely to benefit from a prophylactic gastrectomy than younger patients because of a shorter life-expectancy and a higher perioperative risk.
- Patients who are older than 75 years should not undergo such a procedure, as their mortality from the procedure outweighs their mortality from gastric cancer.
- Decisions should be individualized based upon their comorbidities and the age of gastric cancer onset in their respective kindred.[6]
Gastric Polyps
- Polypectomy should be performed for all known neoplastic polyps and for all polyps ≥1 cm in diameter, as biopsies alone cannot exclude foci of high-grade dysplasia or early gastric cancer.
- In patients with multiple polyps, the largest polyp should be excised and representative biopsies should be obtained from the remaining polyps.
- Fundic gland polyps are associated with a low risk of progression to cancer.
- Small proximal gastric polyps should be biopsied in patients with familial adenomatous polyposis (FAP) to confirm their histology.
- Large or irregular appearing polyps should be biopsied or resected completely to assess for dysplasia.
- Low-grade dysplasia is common in fundic gland polyps, but surgery should be reserved for high-grade dysplasia or cancer.
- Antral polyps are usually adenomas and should be completely resected endoscopically if possible. ?
Hyperplastic polyps
- Hyperplastic polyps occur in association with H. pylori-related atrophic gastritis.
- Surveillance with upper endoscopy should be performed based on the risk factors for gastric cancer one year after initial resection of adenomatous gastric polyps.
- In individuals at high risk for gastric cancer, surveillance is continued long life.
Juvenile Polyposis Syndrome
- Screening the upper gastrointestinal tract with upper endoscopy starting at the age of 12 years.
- If polyps are detected, upper endoscopy should be repeated annually.
- In the absence of upper gastrointestinal tract polyps, upper endoscopy can be performed every two to three years.
Lynch Syndrome
- Individuals with a germline mutation in the DNA mismatch repair MMR or EPCAM genes have a definitive diagnosis of Lynch syndrome and should undergo screening for Lynch syndrome associated cancers.
- Extent of screening in these individuals can be individualized based on their personal and family cancer history and evidence of microsatellite instability on tumor testing.
- Individuals at risk for Lynch syndrome include:
- Individuals in families meeting Amsterdam I or II criteria or revised Bethesda guidelines
- Endometrial cancer prior to age 50 years
- First-degree relative of those with known MMR/EPCAM gene mutation
- Individuals with >5 percent chance of an MMR gene mutation
References
- ↑ 1.0 1.1 Park JY, von Karsa L, Herrero R (November 2014). "Prevention strategies for gastric cancer: a global perspective". Clin Endosc. 47 (6): 478–89. doi:10.5946/ce.2014.47.6.478. PMC 4260094. PMID 25505712.
- ↑ García Martín R, Matía Cubillo Á (May 2016). "[INFLUENCE OF DIET IN PRIMARY PREVENTION OF GASTRIC CANCER, IN PATIENTS INFECTED WITH HELICOBACTER PYLORI]". Rev Enferm (in Spanish; Castilian). 39 (5): 33–8. PMID 27405145.
- ↑ Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S; et al. (1999). "Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation". Am J Pathol. 155 (2): 337–42. doi:10.1016/S0002-9440(10)65129-2. PMC 1866861. PMID 10433926.
- ↑ Pharoah PD, Guilford P, Caldas C, International Gastric Cancer Linkage Consortium (2001). "Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families". Gastroenterology. 121 (6): 1348–53. PMID 11729114.
- ↑ Norton JA, Ham CM, Van Dam J, Jeffrey RB, Longacre TA, Huntsman DG; et al. (2007). "CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer". Ann Surg. 245 (6): 873–9. doi:10.1097/01.sla.0000254370.29893.e4. PMC 1876967. PMID 17522512.
- ↑ Chun YS, Lindor NM, Smyrk TC, Petersen BT, Burgart LJ, Guilford PJ; et al. (2001). "Germline E-cadherin gene mutations: is prophylactic total gastrectomy indicated?". Cancer. 92 (1): 181–7. PMID 11443625.